IP Library Granted Patent US 8,858,993
Granted Patent B2
US 8,858,993 · App. 11/488,547 · Granted Oct 14, 2014

Coated tablet with zero-order or near zero-order release kinetics

Inventors: Thomas B. Gold (Greenville, NC); Patrick Brian Woodall (Greenville, NC)
Assignee: Metrics, Inc.
A61K9/2031A61K9/2866
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,858,993
App. No.
11/488,547
Granted
Oct 14, 2014
Kind
B2
Abstract

Tablets for the controlled release of an active ingredient in a zero-order or near zero-order fashion are provided. The tablet includes a core and a coating. The core includes at least one active pharmaceutical agent and a polyethylene oxide with a molecular weight of between about 1,000,000 and 10,000,000, preferably between about 4,000,000 and 8,000,000. The core material is optionally, but preferably, coated with a cellulosic material. The active pharmaceutical agent can be hydrophilic, hydrophobic, or amphiphilic. When the active pharmaceutical agent is a hydrophilic agent, it is preferred that the coating is a relatively hydrophobic cellulose, such as ethylcellulose or propylcellulose. However, if the tablet is uncoated, it can provide a near-zero-order release rate rather than a zero-order release rate. When the active pharmaceutical agent is a hydrophobic or amphiphilic agent, the hydrophilic polymeric carrier is the same as in the first embodiment, the coating is a relatively more hydrophilic cellulose. The release rate for the active pharmaceutical agent can be controlled by adjusting the thickness of the coating, and, optionally, by adjusting the concentration of the polymeric excipients, as well as certain non-polymeric excipients which may optionally be present. An advantage of using relatively high molecular weight polyethylene oxide is that the release is pH independent, unlike where ionic polymers such as polyacrylic acids are used. Further, active pharmaceutical agents including functional groups that might react with such polymers can be used without an adverse reaction between the active agent and the polymer.

Claims (14)

1. A zero-order or near-zero-order drug delivery device, comprising a tablet with a core formed of a mixture consisting essentially of:

a) a hydrophilic drug;

b) a polyethylene oxide with a molecular weight between about 1,000,000 and 10,000,000; and

(c) a mixture consisting of 80% polyvinyl acetate, 19% polyvinyl pyrrollidone, 0.8% sodium lauryl sulfate, and about 0.2% of silica,

wherein the core is spray coated with a pH independent ethylcellulose, and

wherein the device erodes at a zero-order or near zero-order release rate upon ingestion, thereby releasing the hydrophilic drug at a zero-order or near zero-order delivery rate.

2. The device of claim 1 , wherein the polyethylene oxide has a molecular weight between about 4,000,000 and 8,000,000.

3. The device of claim 1 , wherein the polyethylene oxide has a molecular weight of 7,000,000.

4. The device of claim 1 , wherein the tablet coating comprises an aqueous ethylcellulose dispersion.

5. The device of claim 1 , wherein the hydrophilic drug is present in a range of between about 1 and 10 percent by weight of the tablet.

6. The device of claim 1 , wherein the release is zero-order.

7. The device of claim 1 , wherein the hydrophilic drug is selected from the group consisting of polysaccharides, peptides, proteins, peptidomimetics, cytokines, nucleotides, nucleosides, genetic materials, toxoids, serum vaccines, combinations thereof, and pharmaceutically acceptable salts thereof.

8. The device of claim 1 , wherein the core controls the hydrophilic drug rate of release.

9. The device of claim 1 , wherein the ethylcellulose is present in a range of between about 1 and 20 percent by weight of the core.

Assignments (7)
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (063543/0374) Recorded Dec 19, 2024
From: JPMORGAN CHASE BANK, N.A.
To: CATALENT GREENVILLE, INC.
Reel/Frame 069751/0241 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT SUPPLEMENT Recorded May 4, 2023
From: CATALENT GREENVILLE, INC.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 063543/0374 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2023
From: MAYNE PHARMA COMMERICAL LLC
To: CATALENT GREENVILLE, INC.
Reel/Frame 062908/0019 →
CHANGE OF NAME Recorded Sep 29, 2016
From: METRICS, INC.
To: MAYNE PHARMA INC.
Reel/Frame 040191/0671 →
RELEASE OF SECURITY INTEREST Recorded Jun 25, 2015
From: MIDCAP FUNDING V, LLC
To: METRICS, INC.
Reel/Frame 035904/0707 →
SECURITY AGREEMENT Recorded Nov 15, 2012
From: METRICS, INC.
To: MIDCAP FUNDING V, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 029309/0523 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2012
From: GOLD, THOMAS B.; WOODALL, PATRICK BRIAN
To: METRICS, INC.
Reel/Frame 029270/0665 →
Continuity (2)
Provisional Application 60702161 · Jul 25, 2005
Related Publication 20070020331A1 · Jan 25, 2007